Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Ultrasound Guided Combined Adductor Canal, Superior Genicular Nerves and Anterior Femoral Cutaneous Nerves Blocks in Comparison With Periarticular Local Anesthesia Infiltration in Primary Total Knee Arthroplasty

10. november 2026 oppdatert av: SAMEH ELSHERBINI

Analgesic Efficacy of Ultrasound Guided Combined Adductor Canal, Superior Genicular Nerves and Anterior Femoral Cutaneous Nerves Blocks in Comparison With Periarticular Local Anesthesia Infiltration in Primary Total Knee Arthroplasty: A Prospective Randomized Trial

Background:

Pain management in total knee arthroplasty continues to evolve especially as an early postoperative analgesia is of paramount importance in achieving patient satisfaction and improving clinical outcomes. The goal of achieving an ideal analgesia modality which facilitates early rehabilitation, prevents knee stiffness, reduces hospital stay due to pain, and promotes good functional outcomes continues to be elusive. Multimodal analgesia has been devised to control postoperative pain and reduce opioid consumption including periarticular injection and peripheral nerve blocks.

Rationale:

Assess the efficacy of a triple block including Adductor canal block, superior lateral, superior medial genicular nerves block and anterior femoral cutaneous nerves block in comparison with Periarticular infiltration for pain management in patients undergoing a total knee arthroplasty.

Methods:

Prospective Randomized Control Trial

Studieoversikt

Detaljert beskrivelse

Pain management after total knee arthroplasty continues to evolve, as effective early postoperative analgesia is essential for patient satisfaction, early mobilization, improved functional outcomes, and reduced hospital stay. Multimodal analgesia strategies have been developed to optimize pain control while minimizing opioid consumption, including periarticular injection and peripheral nerve blocks.

Femoral nerve block has traditionally been used for analgesia after total knee arthroplasty; however, its associated quadriceps weakness may delay mobilization and increase the risk of falls. Consequently, the adductor canal block has gained popularity because it provides predominantly sensory blockade while preserving quadriceps muscle strength.

The sensory innervation of the knee joint is complex and involves branches from the femoral, tibial, common peroneal, saphenous, and obturator nerves. Genicular nerve blocks specifically target the sensory innervation of the knee capsule and have emerged as a promising technique for postoperative pain management. In this study, higher volumes of local anesthetic will be used for the superior genicular nerve blocks to improve coverage of the posterior knee capsule, while the inferolateral genicular nerve block will be avoided because of the potential risk of motor weakness and foot drop.

As the medial parapatellar approach is the most common surgical approach for total knee arthroplasty, the anterior femoral cutaneous nerve, which supplies the anteromedial aspect of the distal thigh and knee, may represent an additional target for postoperative analgesia.

Periarticular injection is a surgeon-administered analgesic technique that provides effective early postoperative pain relief without affecting quadriceps strength and has become widely adopted in total knee arthroplasty.

The aim of this study is to compare the analgesic efficacy of a combined approach using adductor canal block, superior genicular nerve blocks, and anterior femoral cutaneous nerve block with periarticular injection in patients undergoing total knee arthroplasty. We hypothesize that adding superior genicular nerve blocks and anterior femoral cutaneous nerve block to adductor canal block will provide superior postoperative analgesia compared with periarticular injection.

A prospective randomized blinded trial will be conducted at Qassim University Hospital after obtaining written informed consent. Adult patients undergoing primary unilateral total knee replacement, aged above 18 years, with a body mass index below 40 kg/m² and American Society of Anesthesiologists physical status I-II will be included. Patients with contraindications to spinal anesthesia, allergy to study medications, opioid dependence, previous knee surgery, chronic neuropathic pain, or regular use of analgesics other than nonsteroidal anti-inflammatory drugs will be excluded.

All patients will undergo routine preoperative assessment and laboratory investigations. In the operating room, standard monitoring will be applied, intravenous access established, and crystalloid infusion commenced.

Spinal anesthesia will be performed under aseptic conditions using hyperbaric bupivacaine, followed by intravenous sedation with midazolam, fentanyl, and propofol infusion. All patients will receive prophylactic antibiotics and tranexamic acid, with supplemental oxygen and capnography monitoring throughout the procedure.

All surgeries will be performed using a standardized surgical technique by the same surgical team, while regional anesthesia procedures will be performed by the same anesthesiologists. Outcome assessors and data analysts will remain blinded to group allocation.

Postoperative analgesia will include regular paracetamol and ketorolac, with intravenous morphine provided as rescue analgesia when required. After discharge, patients will receive oral paracetamol and celecoxib, with tramadol and antiemetics prescribed as needed.

Studietype

Intervensjonell

Registrering (Antatt)

112

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Al-Qassim Region
      • Buraidah, Al-Qassim Region, Saudi-Arabia
        • Rekruttering
        • Qassim University Medical City
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. ASA: I - II
  2. Gender: Male & Female
  3. Age: 18and above
  4. BMI less than 40 kg/m2
  5. Patients are scheduled for primary unilateral total knee arthroplasty.

Exclusion Criteria:

  1. Patients with contraindications to spinal anesthesia
  2. Failed spinal anesthesia.
  3. ASA III - IV
  4. Body mass index (BMI)≥40,
  5. A known allergy or contraindication to the drugs used in this study.
  6. Previous surgery at the same knee
  7. Renal impairment.
  8. Patients who suffer from chronic neuropathic pain or on regular pain medications other than NSAIDs.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Periarticular Infiltration Analgesia Group

It will be infiltrated by the surgeon before prosthesis implantation.

A total volume of 50 mL containing 49 mL bupivacaine 0.25% and dexamethasone 8 mg will be infiltrated by the surgeon before prosthesis implantation into the posterior capsule, medial and lateral gutters, quadriceps mechanism, patellar tendon, and medial periosteum.

Aktiv komparator: Triple Block Group

Patients will receive ultrasound-guided adductor canal, infrapatellar, medial cutaneous, and superior genicular nerve blocks.

Patients will receive a mixture of 45 mL of 0.25% bupivacaine and 8 mg dexamethasone. A total of 15 mL will be injected into the adductor canal, 10 mL for the anterior femoral cutaneous nerve blocks, and 10 mL each for the superior medial and superior lateral genicular nerve blocks.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
End of Analgesia Time
Tidsramme: Within the first 24 hours after surgery.

Time from spinal anesthesia until the first Numeric Rating Scale (NRS) pain score ≥ 4. Analysed as time-to-event using Kaplan-Meier curves and the log-rank test (Cox regression if needed). Patients without pain (NRS ≥4) by 24 hours are censored at 24 hours

Within the first 24 hours after surgery.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Total Morphine Consumption (mg)
Tidsramme: From end of surgery until hospital discharge (same day, approximately 6 to 9 hours)

Total cumulative morphine consumption during hospital stay

From end of surgery until hospital discharge (same day, approximately 6 to 9 hours)
Total Tramadol Consumption (number of capsules)
Tidsramme: From hospital discharge until the last diary entry (approximately 16 hours after arrival home)

Total tramadol consumption after hospital discharge

From hospital discharge until the last diary entry (approximately 16 hours after arrival home)
Heart rate (Beat/minute)
Tidsramme: From end of surgery until hospital discharge, assessed up to 12 hours

Heart rate measurements recorded postoperatively every 30 minutes in the recovery unit, then hourly in the day surgery unit until discharge.

From end of surgery until hospital discharge, assessed up to 12 hours
Blood pressure (mmHg)
Tidsramme: From end of surgery until hospital discharge, assessed up to 12 hours

Blood pressure measurements recorded postoperatively every 30 minutes in the recovery unit, then hourly in the day surgery unit until discharge.

From end of surgery until hospital discharge, assessed up to 12 hours
Patient Satisfaction Score
Tidsramme: At 24 hours after the end of surgery

Patient satisfaction with postoperative analgesia rated on a numeric scale from 0 (completely dissatisfied) to 10 (completely satisfied), obtained by telephone call.

At 24 hours after the end of surgery
Length of Hospital Stay
Tidsramme: From operating room admission until same-day hospital discharge, assessed up to 24 hours

Minutes

From operating room admission until same-day hospital discharge, assessed up to 24 hours
NRS pain score at each time point
Tidsramme: From PACU arrival until the last home diary entry, assessed up to 24 hours

NRS (0-10) recorded at PACU arrival, 30, 60, 90 and 120 min, then at DSU arrival and hourly until discharge, and at set intervals in the home diary

From PACU arrival until the last home diary entry, assessed up to 24 hours
Time to first ambulation
Tidsramme: From DSU arrival until first ambulation, assessed up to 12 hours

Minutes from DSU arrival to first ambulation

From DSU arrival until first ambulation, assessed up to 12 hours
Postoperative nausea and vomiting
Tidsramme: From PACU arrival until hospital discharge, assessed up to 12 hours

Incidence of PONV and antiemetic use (number of episodes and dose)

From PACU arrival until hospital discharge, assessed up to 12 hours

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: OMAR S Almisnid, Anesthesia Consultant, Department of Anesthesia, College of Medicine, Qassim University

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

20. oktober 2026

Primær fullføring (Antatt)

30. mars 2027

Studiet fullført (Antatt)

1. april 2027

Datoer for studieregistrering

Først innsendt

5. juli 2026

Først innsendt som oppfylte QC-kriteriene

10. juli 2026

Først lagt ut (Faktiske)

15. juli 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere